Skip to main content

Table 6 DBPCFC and IFE stopping rules

From: Protocol for a double-blind, randomized controlled trial on the dose-related efficacy of omalizumab in multi-food oral immunotherapy

  1. Stopping rules based on the PRACTALL scoring system. Challenge will be stopped when any symptom reaches the red or when 2 symptoms from different categories reach the yellow. Adapted from Sampson et al. [47]
Back to article page

Allergy, Asthma & Clinical Immunology

ISSN: 1710-1492

Contact us